Can a fentanyl spray stop pain during cancer radiation?
NCT ID NCT02426697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 trial tested whether a fentanyl spray (Pecfent) could prevent pain when moving patients with bone metastases during radiotherapy. 39 adults with cancer that spread to bone and who had pain during positioning for radiation took part. The study compared fentanyl to a placebo to see if it reduced pain scores.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- fentanyl transmucosal (Pecfent)
- What this could lead to
- If effective, this could offer a way to prevent pain during radiotherapy sessions for people with bone metastases, making treatment more comfortable.
- What could go wrong
- This is a small, completed Phase 3 trial with only 39 participants, so results may not apply to everyone. Fentanyl is a strong opioid with risks like addiction and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
39 people
The number who actually took part.
- Started
-
May 2015
- Finished
-
Apr 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female * More than 18 years old * Proven histological cancer with bone metastasis * SignedInform consent form * Patient with pain assed as VAS Superior to 3 when positioning the patient in the preliminary scanner session Exclusion Criteria: * VAS\>3 before radiotherapy treatment (establishment of an appropriate analgesic treatment) (session * Any SAO treatment on going * Pregnant or lactating woman * Hypersensitivity or safety issues to any opioïd treatment * Poor nasal mucosa (defined on clinical doctor assessment) * Severe obstructive lung conditions or respiratory depression * Renal insufficiency with creatinine clearance inferior to 45 ml/min * Hepatic insufficiency * Patient misunderstanding of the content and objective of the trial * Patient under supervision or guardianship * SAO intake 4 hours before the radiotherapy session * Patient participating to any other pain management trial * Morphine pump usage
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone metastasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Henri Becquerel
Rouen, 76038, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.